

The roles of coenzyme Q₁₀ and vitamin E on the peroxidation of human low density lipoprotein subfractions

(fatty acids)

R. ALLEVA*[†], M. TOMASETTI*, M. BATTINO*, G. CURATOLA*, G. P. LITTARRU*, AND K. FOLKERS[‡]

*Institute of Biochemistry, Faculty of Medicine, University of Ancona, via Ranieri, 60131 Ancona, Italy; and [‡]Institute for Biomedical Research, University of Texas, Austin, TX 78712

Contributed by Karl Folkers, May 25, 1995

ABSTRACT The aim of our study was to investigate the relationships between the levels of coenzyme Q₁₀ (CoQ₁₀) and vitamin E and the levels of hydroperoxide in three subfractions of low density lipoproteins (LDL) that were isolated from healthy donors. LDL₃, the densest of the three subfractions, has shown statistically significant lower levels of CoQ₁₀ and vitamin E, which were associated with higher hydroperoxide levels when compared with the lighter counterparts. After CoQ₁₀ supplementation, all three LDL subfractions had significantly increased CoQ₁₀ levels. In particular, LDL₃ showed the highest CoQ₁₀ increase when compared with LDL₁ and LDL₂ and was associated with a significant decrease in hydroperoxide level. These results support the hypothesis that the CoQ₁₀ endowment in subfractions of LDL affects their oxidizability, and they have important implications for the treatment of disease.

Atherogenic changes in low density lipoproteins (LDL) are likely related to oxidative events that can occur in some circulation districts, such as the subendothelial space (1). Oxidized LDL are believed to contribute to the atherogenic process by altering chemotaxis of monocytes and monocyte-derived macrophages, which can engorge the oxidatively modified particles through the scavenger receptor-mediated mechanism (2, 3). Furthermore, they promote endothelial damage and other changes also associated with atherogenesis (4). Although a relationship between oxidizability and chemical composition of LDL has been widely investigated, the relative importance of different constituents in preventing oxidation of LDL remains uncertain (5, 6). It was recently suggested that antioxidants in LDL were one of the crucial factors in determining the propensity of LDL to oxidation (7). In particular, coenzyme Q₁₀ (CoQ₁₀), an important antioxidant associated with LDL, was reported to protect the particles of lipoprotein more efficiently than does vitamin E (8, 9). Recall that particles of LDL are heterogeneous and differ in size, density, and chemical composition. Recent reports have shown an increased susceptibility to oxidation in the most dense of three LDL subfractions (10, 11); this subfraction is more abundant in individuals having coronary heart disease than in healthy and normal subjects (12, 13).

To clarify the influence of an endogenous antioxidant on the susceptibility to oxidation, we assayed the levels of peroxidation products in the LDL subfractions in relation to the levels of CoQ₁₀ and vitamin E. We assayed the levels of hydroperoxide in the LDL subfractions, both under basal conditions and after an exogenous radical insult, in a group of normal young volunteers before and after oral supplementation with CoQ₁₀. Because the susceptibility of LDL particles also depends on their levels of an oxidizable substrate (14), the

relative amounts of free fatty acids in each LDL subfraction were also considered.

MATERIALS AND METHODS

Subjects. The subjects enrolled in this study were 10 healthy male volunteers (mean age, 26 ± 4) who were not taking any drugs. They were members of a religious community, and they had a common diet and life-style. The study was approved by the appropriate university committee and after informed consent was obtained. Plasma was collected into EDTA-containing tubes before and after oral supplementation with CoQ₁₀ at a dosage of 100 mg per day for 30 days.

Isolation of LDL Subfractions. Three LDL subfractions (LDL₁ ρ = 1.030–1.033 g/ml; LDL₂ ρ = 1.033–1.040 g/ml; LDL₃ ρ = 1.040–1.045 g/ml) were isolated from freshly collected plasma by means of density-gradient ultracentrifugation during 20 hr at 14°C and at 36,000 rpm (10). After isolation, the LDL subfractions were dialyzed for 24 hr at 4°C against 0.01 M phosphate buffer (pH 7.4) containing 0.16 M NaCl and a chelating resin (Chelex 100, Sigma).

Plasma and Lipoprotein Composition. The lipid patterns in whole plasma and in each subfraction were assessed with commercially available enzymatic kits on the Synchron-Beckmann analyzer (15, 16).

Protein levels were determined by the method of Lowry *et al.* (17).

Fatty acid levels in plasma and in the LDL subfractions were determined by capillary gas chromatography after transesterification, as described by Lepage and Roy (18), on a Hewlett-Packard 5890 series II chromatograph, equipped with a 60 m × 0.32 mm i.d. fused-silica capillary column.

Determination of CoQ₁₀ and Vitamin E. The levels of CoQ₁₀ (in the oxidized form) and vitamin E in the LDL subfractions and in the plasma of each subject were determined using HPLC, as described (19).

Assay of Hydroperoxide. The lipid hydroperoxides were determined before and after peroxidation as induced by 2,2-azobis(2-amidinopropane) dihydrochloride (AAPH), a water-soluble azo compound, which thermally decomposes to produce peroxy radicals (20). The assay was based on ferrous ion oxidation in the presence of xylenol orange (21). Samples (100 μg of LDL protein) of each subfraction were exposed to 2 mM AAPH (final concentration) for 120 min at 37°C in a shaking water bath. Lipid hydroperoxides were estimated spectrophotometrically at 560 nm on a Beckmann model spectrophotometer. Susceptibility to peroxidation was expressed as the increase in hydroperoxides after exposure to AAPH and in respect to basal hydroperoxides.

Statistical Analysis. The results are expressed as means ± SD. The mean differences in composition and oxidation

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Abbreviations: CoQ₁₀, coenzyme Q₁₀; LDL, low density lipoprotein(s); AAPH, 2,2-azobis(2-amidinopropane) dihydrochloride.
[†]To whom reprint requests should be addressed.

Table 1. Lipid, CoQ₁₀, and vitamin E levels and fatty acid composition in plasma

Substance	Plasma composition
Cholesterol, mg/dl	162.8 ± 28.3
Triglycerides, mg/dl	88.4 ± 21.8
Phospholipids, mg/dl	174.8 ± 24.7
CoQ ₁₀ , µg/ml	
Before supplementation	0.6 ± 0.1
After supplementation	1.5 ± 0.3*
Vitamin E, µg/ml	10.5 ± 3.1
Fatty acids, %	
14:0	
16:0	21.7 ± 0.7
16:1	1.5 ± 0.3
18:0	8.3 ± 1.1
18:1	17.4 ± 0.61
18:2	32.7 ± 1.0
20:4	6.6 ± 0.5
Unsaturated	67.1 ± 1.5
Saturated	32.9 ± 1.5
Polyunsaturated	45.8 ± 2.7
Unsaturation index	4.3 ± 0.3

*Data are statistically significant at $P < 0.01$.

parameters in the LDL subclasses were evaluated by ANOVA using STAT VIEW II ANOVA tests on a Macintosh LC computer.

RESULTS

Whole Plasma. The levels of lipids, CoQ₁₀, and vitamin E in plasma are shown in Table 1. No significant difference in the lipid patterns was found after CoQ₁₀ supplementation in comparison with the basal levels.

LDL Subfractions Before CoQ₁₀ Supplementation. The results on the lipid and apoprotein compositions are in accordance with de Graaf *et al.* (10). The fatty acid composition of LDL subfractions showed a higher percentage of the unsaturated fatty acids in LDL₁ and LDL₂ subfractions as compared with LDL₃ subfraction (Table 2). In particular, the levels of arachidonic and linoleic acids were significantly higher in LDL₁ and LDL₂ subfractions in comparison with LDL₃ subfraction, and LDL₃ subfraction had the highest level of palmitic acid. The levels of CoQ₁₀ and vitamin E were significantly lower in LDL₃ subfraction than in LDL₁ and LDL₂ subfractions in all subjects ($P < 0.01$; Figs. 1 and 2). This study of LDL peroxidation showed increased "basal" levels of hydroperoxides in LDL₃ subfraction with respect to LDL₁ and LDL₂ subfractions ($P < 0.01$; Fig. 3).

After exposure to AAPH, the levels of hydroperoxide were slightly higher in LDL₃ in comparison with the other two subfractions, although the differences were not significant

Table 2. Fatty acid composition of LDL subfractions

Fatty acid	Fatty acid composition, %		
	LDL ₁	LDL ₂	LDL ₃
16:0	21.6 ± 0.7	20.4 ± 1.2	21.2 ± 0.9
16:1	1.5 ± 0.3	2.3 ± 0.8	0.8 ± 0.1
18:0	9.5 ± 1.1	11.8 ± 5.2	41.4 ± 12.3*
18:1	17.4 ± 0.6	16.1 ± 2.5	8.5 ± 3.6
18:2	33.7 ± 1.0	30.1 ± 4.4	13.1 ± 6.7*
20:4	6.6 ± 0.5	5.7 ± 0.9	2.0 ± 0.2†
Unsaturated	67.2 ± 1.5	64.4 ± 5.2	32.2 ± 14.2*
Saturated	32.8 ± 1.5	35.6 ± 5.2	67.8 ± 14.2*
Polyunsaturated	44.5 ± 2.8	43.9 ± 2.9	22.5 ± 4.4
Unsaturation index	4.3 ± 0.3	4.2 ± 0.6	1.4 ± 0.6*

*Data are statistically significant at $P < 0.01$.

†Data are statistically significant at $P < 0.05$.




Fig. 1. CoQ₁₀ levels in LDL subfraction before and after CoQ₁₀ supplementation. ○, LDL₃ vs. LDL₁ and LDL₂, $P < 0.001$; ●, LDL₃ vs. LDL₁ and LDL₂, $P < 0.01$; ▲, LDL₁, LDL₂, and LDL₃ vs. LDL₁, LDL₂, and LDL₃ after CoQ₁₀ supplementation, $P < 0.01$.

(Fig. 4). No relevant differences in lipid peroxidation susceptibility were found among the three LDL subfractions. Susceptibility was considered as an increase in levels of lipid hydroperoxides after incubation with AAPH in comparison with basal levels (Fig. 5).

LDL Subfractions After CoQ₁₀ Supplementation. No significant difference was found in lipoprotein composition after CoQ₁₀ supplementation. The levels of CoQ₁₀ were significantly increased in all three subfractions ($P < 0.01$) of every subject. LDL₃ showed the highest increase in the level of CoQ₁₀ after supplementation, and the posttreatment level was lower than the corresponding levels in LDL₁ and LDL₂ subfractions (Fig. 1).

A small increase in the level of vitamin E was observed in all three subfractions and was statistically significant in LDL₂ and LDL₃ subfractions ($P < 0.05$; Fig. 2). The basal levels of hydroperoxide showed a different trend in the three LDL subfractions. In LDL₁ and LDL₂ subfractions the basal hydroperoxide levels were unchanged. LDL₃ subfraction showed a significant decrease in hydroperoxide levels when compared with the levels before CoQ₁₀ supplementation (Fig. 3). A




Fig. 2. Vitamin E levels. ○, LDL₃ vs. LDL₁ and LDL₂ before CoQ₁₀, $P < 0.001$; ●, LDL₂ before CoQ₁₀ supplementation, $P < 0.001$; ▲, LDL₃ vs. LDL₂ and LDL₃ before CoQ₁₀ supplementation, $P < 0.05$.




FIG. 3. Hydroperoxide basal levels. ○, LDL₃ vs. LDL₁ and LDL₂ before CoQ₁₀ supplementation, $P < 0.001$; ▲, LDL₃ basal levels before vs. after CoQ₁₀ supplementation, $P < 0.001$.

decrease of the hydroperoxide levels (after AAPH-induced oxidation) was seen in all three subfractions, but there was statistical significance in the difference for only LDL₃. The decrease of susceptibility to oxidation was significant for LDL₁ and LDL₃ (Figs. 4 and 5).

DISCUSSION

Elevated levels of LDL₃ are commonly found in patients with coronary artery disease or at high risk for coronary artery disease. The increased susceptibility of LDL₃, as found by de Graaf *et al.* (10), might be, in part, responsible for the atherogenic status of this subpopulation. The higher oxidative susceptibility of LDL₃ might also be from the lower endogenous concentrations of antioxidants as compared with LDL₁ and LDL₂ subfractions (8). Our study demonstrates that LDL₃ contains lower levels of CoQ₁₀ and vitamin E, which are associated with higher hydroperoxide levels in comparison with LDL₁ and LDL₂ subfractions.

We cannot demonstrate that the hydroperoxide levels represent endogenous levels because they are often regarded as arising from consequences of *in vitro* manipulation of LDL during the isolation. We might reasonably suppose that LDL₃




FIG. 4. Hydroperoxide-induced levels. ▲, LDL₃ before vs. LDL₃ after CoQ₁₀ supplementation, $P < 0.001$.




FIG. 5. Peroxidation susceptibility. ●, LDL₁ before vs. LDL₁ after CoQ₁₀, $P < 0.05$; ▲, LDL₃ before vs. LDL₃ after CoQ₁₀, $P < 0.01$.

is more susceptible to hydroperoxide formation during the usual LDL isolation procedures. The relationship between CoQ₁₀ level in LDL and oxidative susceptibility is supported by data obtained after oral supplementation with CoQ₁₀. LDL₃ subfraction, which had the greatest increase in CoQ₁₀ after supplementation, also showed a significant decrease of the levels of both basal and "AAPH-elicited" hydroperoxide, when compared with LDL₁ and LDL₂. It is important that susceptibility to peroxidation decreased in all three subfractions, and these decreases were statistically significant for LDL₁ and LDL₃ subfractions.

Our results confirm that CoQ₁₀ is an important antioxidant that can lower the susceptibility of LDL to oxidation. When considering the remarkable increase of CoQ₁₀ in LDL₃ subfraction after supplementation, it is possible to hypothesize a different degree of "unsaturation" in CoQ₁₀ for different LDL subfractions. LDL₃ subfraction appears to be the one that contains the lowest CoQ₁₀ levels with the highest peroxide levels. Even though the administration of CoQ₁₀ influenced susceptibility to peroxidation, especially regarding LDL₁ and LDL₃ subfractions, we did not find significant differences in susceptibility among the three subfractions. Besides the antioxidant activity of LDL subfractions, their oxidizability is also affected by the polyunsaturated fatty acids available for oxidation. In particular, the relative abundance of arachidonic and linoleic acid is associated with a higher oxidative susceptibility. As suggested (22), LDL particles depleted of their antioxidant were more resistant to oxidative stress when the subjects consumed a diet with monounsaturated acids compared with polyunsaturated acids. The free fatty acids in our LDL subfractions differ significantly in their unsaturation index. There was a higher content of unsaturated fatty acids in LDL₁ and LDL₂ subfractions than in LDL₃ subfraction. Higher levels of linoleic and arachidonic acid were found in LDL₁ and LDL₂ subfractions than in LDL₃ subfraction. This fatty acid pattern could explain the similar susceptibility exhibited by the different LDL subfractions, even though significant differences in levels of CoQ₁₀ and vitamin E were present. The lower levels of CoQ₁₀ and vitamin E could be a cause of the higher levels of the hydroperoxides when compared with lower levels after oral supplementation with CoQ₁₀. Susceptibility can be related to the fatty acid composition of LDL₃ subfraction and counterbalance the peroxidative effect of a low level of antioxidants. Parthasarathy *et al.* (23) suggested that a reduction of the polyunsaturated fatty acids in LDL should reduce the "consumption" of antioxidants. Be-

cause the subjects in our study constituted a remarkably homogeneous group, our results are probably not affected by differences in diets and/or life-styles, which may amplify differences in composition and oxidizability of LDL subfractions.

In conclusion, our data support the concept that the CoQ₁₀ level of the LDL subfractions is important in minimizing susceptibility of LDL subfractions to oxidation. The chemical composition of the LDL subfractions, especially in fatty acids, affects lipoprotein peroxidation susceptibility. Further investigations to assess LDL oxidizability should evaluate the lipid composition of diets together with the antioxidation status in normal subjects and patients.

This work was supported, in part, by grants from Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Rome, Italy. Ubiquinone homologs were the kind gift of Eisai Co., Tokyo. (+)- α -Tocopherol and (+)- α -tocopheryl acetate were a gift from Henkel Co., La Grange, IL.

- Hessler, J. R., Robertson, A. L., Jr., & Chilsom, G. M. (1979) *Atherosclerosis (Dallas)* **32**, 213–229.
- Quinn, M. T., Parthasarathy, S., Fong, L. F. & Steinberg, D. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 2995–2998.
- Quinn, M. T., Parthasarathy, S. & Steinberg, D. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 2805–2809.
- Morel, D. W., Hessler, J. R. & Chilsom, G. M. (1983) *J. Lipid Res.* **4**, 1070–1076.
- Esterbauer, H., Gebicki, J., Puhl, H. & Jürgens, G. (1992) *Free Radical Biol. Med.* **13**, 341–390.
- Esterbauer, H., Dieber-Rotheneder, M., Waeg, G., Streigel, G. & Jürgens, G. (1990) *Chem. Res. Toxicol.* **3**, 77–92.
- Esterbauer, H., Dieber-Rotheneder, M., Striegel, G. & Waeg, G. (1991) *Am. J. Clin. Nutr.* **53**, 314S–321S.
- Stocker, R., Bowry, V. W. & Frei, B. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 1646–1650.
- Ingold, K., Bowry, V. W., Stocker, R. & Wailing, C. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 45–49.
- de Graaf, J., Hak-Lemmers, L. M., Hectors, M., Demacker, P., Hendricks, J. & Stalenhoef, A. (1991) *Arterioscler. Thromb.* **11**, 298–306.
- Chait, A., Brazg, R. L., Tribble, D., & Krauss, R. M. (1993) *Am. J. Med.* **94**, 350–356.
- Austin, M. A., Breslow, J. L., Hennekens, C. H., Biring, J. E., Willett, W. C. & Krauss, R. M. (1988) *J. Am. Med. Assoc.* **260**, 1917–1921.
- Campos, H., Genest, J. J., Blijlevens, E., McNamara, J. R., Jenner, J. L., Ordovas, J. M., Wilson, P. W. F. & Shaefer, E. J. (1992) *Arterioscler. Thromb.* **12**, 187–195.
- Kleinveld, H. A., Naber, A. H. J., Stalenhoef, A. F. H. & Demacker, P. N. M. (1993) *Free Radical Biol. Med.* **15**, 273–280.
- Warnick, G. R. (1986) *Methods Enzymol.* **129**, 101–123.
- Bucolo, G., David, H. (1973) *Clin. Chem.* **20**, 470–475.
- Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. (1951) *J. Biol. Chem.* **193**, 265–275.
- Lepage, G. & Roy, C. R. (1986) *J. Lipid Res.* **27**, 114–120.
- Littarru, G. P., Lippa, S., Oradei, A., Fiorini, R. M. & Mazzanti, L. (1990) in *Biomedical and Clinical Aspects of Coenzyme Q*, eds. Folkers, K., Littarru, G. P. & Yamagami, T. (Elsevier, Amsterdam), Vol. 6, pp. 167–178.
- Barclay, L. R. C., Locke, S. J., MacNeil, J. M., Van Kessel, J., Burton, G. W. & Ingold, K. U. (1984) *J. Am. Chem. Soc.* **106**, 2479–2481.
- Zhen-Yue, J., Hunt, J. & Wolff, S. P. (1992) *Anal. Biochem.* **202**, 384–389.
- Bonanone, A., Pagnan, A., Biffanti, S., Opportuno, A., Sorgato, F., Dorella, M., Maiorino, M. & Ursini, F. (1992) *Arterioscler. Thromb.* **12**, 529–533.
- Parthasarathy, S., Khoo, J. C., Miller, E., Barnett, J., Witzum, J. L. & Steinberg, D. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 3894–3898.